Long-term cardiovascular risks and the impact of statin treatment on socioeconomic inequalities: a microsimulation model

Br J Gen Pract. 2024 Feb 29;74(740):e189-e198. doi: 10.3399/BJGP.2023.0198. Print 2024 Mar.

Abstract

Background: UK cardiovascular disease (CVD) incidence and mortality have declined in recent decades but socioeconomic inequalities persist.

Aim: To present a new CVD model, and project health outcomes and the impact of guideline-recommended statin treatment across quintiles of socioeconomic deprivation in the UK.

Design and setting: A lifetime microsimulation model was developed using 117 896 participants in 16 statin trials, 501 854 UK Biobank (UKB) participants, and quality-of-life data from national health surveys.

Method: A CVD microsimulation model was developed using risk equations for myocardial infarction, stroke, coronary revascularisation, cancer, and vascular and non-vascular death, estimated using trial data. The authors calibrated and further developed this model in the UKB cohort, including further characteristics and a diabetes risk equation, and validated the model in UKB and Whitehall II cohorts. The model was used to predict CVD incidence, life expectancy, quality-adjusted life years (QALYs), and the impact of UK guideline-recommended statin treatment across socioeconomic deprivation quintiles.

Results: Age, sex, socioeconomic deprivation, smoking, hypertension, diabetes, and cardiovascular events were key CVD risk determinants. Model-predicted event rates corresponded well to observed rates across participant categories. The model projected strong gradients in remaining life expectancy, with 4-5-year (5-8 QALYs) gaps between the least and most socioeconomically deprived quintiles. Guideline-recommended statin treatment was projected to increase QALYs, with larger gains in quintiles of higher deprivation.

Conclusion: The study demonstrated the potential of guideline-recommended statin treatment to reduce socioeconomic inequalities. This CVD model is a novel resource for individualised long-term projections of health outcomes of CVD treatments.

Keywords: Markov microsimulation model; cardiovascular disease; individual patient characteristics; inequality; quality-adjusted life years; socioeconomic status.

MeSH terms

  • Adult
  • Aged
  • Cardiovascular Diseases* / epidemiology
  • Female
  • Heart Disease Risk Factors
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors* / therapeutic use
  • Incidence
  • Life Expectancy
  • Male
  • Middle Aged
  • Quality-Adjusted Life Years
  • Risk Assessment
  • Socioeconomic Factors*
  • United Kingdom / epidemiology

Substances

  • Hydroxymethylglutaryl-CoA Reductase Inhibitors